Home0775 • HKG
CK Life Sciences Intl (Holdings) Inc
$0.41
Jan 16, 8:35:03 AM GMT+8 · HKD · HKG · Disclaimer
StockHK listed security
Previous close
$0.41
Year range
$0.30 - $0.62
Market cap
3.94B HKD
Avg Volume
887.22K
P/E ratio
-
Dividend yield
-
Primary exchange
HKG
Market news
Financials
Income Statement
Revenue
Net income
(HKD)Jun 2024Y/Y change
Revenue
1.32B2.20%
Operating expense
323.51M-4.23%
Net income
500.50K-97.29%
Net profit margin
0.04-97.20%
Earnings per share
——
EBITDA
117.12M36.03%
Effective tax rate
79.96%—
Total assets
Total liabilities
(HKD)Jun 2024Y/Y change
Cash and short-term investments
562.09M11.10%
Total assets
10.89B-1.45%
Total liabilities
6.87B-0.11%
Total equity
4.01B—
Shares outstanding
9.61B—
Price to book
0.98—
Return on assets
1.75%—
Return on capital
1.91%—
Net change in cash
(HKD)Jun 2024Y/Y change
Net income
500.50K-97.29%
Cash from operations
72.70M80.63%
Cash from investing
-47.88M-484.81%
Cash from financing
-77.72M41.39%
Net change in cash
-57.56M42.02%
Free cash flow
35.56M91.21%
About
CK Life Sciences International Inc., or CK Life Sciences, is a subsidiary of CK Hutchison Holdings. It is engaged in research and development, commercialization, marketing and sale of biotechnology products. The chairman is Mr. Victor Li, the elder son of Mr. Li Ka-shing, the chairman of Cheung Kong Holdings. It was established in 2000 and listed on the Hong Kong Stock Exchange via Growth Enterprise Market in 2002. It was transferred to Main Board of the Hong Kong Stock Exchange in 2008. CK Life Sciences has operations in Australia, and in 2012 acquired an Australian salt company as part of its expansion into the agricultural sector. The company divested its Canadian subsidiary WEX Pharmaceuticals to Virios Therapeutics for $100 million in October 2024. Wikipedia
Founded
2000
Employees
1,968
Search
Clear search
Close search
Google apps
Main menu